From

Institution

Field

Type

Journal / venue: Annals of Oncology ×

Open access only Cited by patents (Lens) Include non-Aachen papers (citing/cited)

Reset

Papers 297

Sort: Cited Newest Oldest Fwci Patents ⇩ CSV

1618P Return to work in the phase III trial NADINA: Neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
2025 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access

J. Lijnsvelt, Maarten Egeler, M.W. Lucas, Alexander Maxwell Menzies, Rachael Lisa Morton, Astrid A.M. van der Veldt, +14 more

0

citations
367P Validation of minimal risk of recurrence classification by the breast cancer index
2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

M-F. Jilderda, JMS Bartlett, Gerrit‐Jan Liefers, Yi Zhang, Hywel Dunn-Davies, Valerie Rebattu, +12 more

0

citations
CN78 Longitudinal study of gastrointestinal symptoms & quality of life after pancreatectomy (GO-PANC)
2025 Annals of Oncology conference-abstract Medicine Cancer survivorship and care Open access

Annuska Schoorlemmer, Chulja J. Pek, Pauline A. J. Vissers, P. Appelhof, L. Baade-Corpelijn, E. Betten, +7 more

0

citations
365P AI-driven evaluation of spatial tumour-infiltrating lymphocytes in a large cohort of systemically untreated, luminal breast cancer patients
2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

Erik J. Blok, M-F. Jilderda, Khalid AbdulJabbar, Haixi Yan, Linda de Munck, R.F. Salgado, +2 more

0

citations
47eP Procedures of data merging in precision cancer medicine: The PRIME-ROSE project
2025 Annals of Oncology article Mathematics Statistical Methods in Clinical Trials Open access

T.M. Kringelbach, Maria Martin Agudo, Gabriel Bratseth Stav, L. Fagereng, Soemeya F. Haj Mohammad, Hans J.L. Timmer, +12 more

0

citations
1535P Model-informed precision dosing of pembrolizumab: Optimizing treatment intervals using NONMEM-based simulations
2025 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

Elise Joëlle Smolders, Zhiping Tan, Erwin de Boer, Jan Willem de Groot, H-B. Fiebrich, Dirk Jan A. R. Moes, +1 more

0

citations
1849MO Updated overall survival analysis from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

M.L. Johnson, Egbert Frederik Smit, Enriqueta Felip, S.S. Ramalingam, M-J. Ahn, Anne S. Tsao, +14 more

0

citations
2756eTiP A prospective international observational study on low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF: A PUSH platform study
2025 Annals of Oncology article Medicine Sarcoma Diagnosis and Treatment Open access

Claudia Giani, Inga‐Marie Schaefer, Elizabeth A. Connolly, Ansley Hong, Cristina R. Antonescu, Elena Bellan, +10 more

0

citations
LBA31 Neoadjuvant immunotherapy induces immune activation and responses in MMR-proficient colon cancers
2025 Annals of Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access

Yara L. Verschoor, Pedro Batista Tan, José G. van den Berg, Sara Balduzzi, Niels F.M. Kok, Marieke E. Ijsselsteijn, +10 more

0

citations
2093eTiP An open-label phase II study of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with advanced NSCLC harbouring EGFR mutations categorised according to structural based classification
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

Jorn Nützinger

0

citations
986P Zongertinib in HER2-mutant advanced NSCLC: Impact of therapy line on efficacy
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations

Y. Wu, Gerrina Ruiter, H. Tu, M-J. Ahn, K. Yoh, J. Zugazagoitia, +13 more

0

citations
542P Effect of a prediction tool and communication skills training on communication of esophagogastric cancer treatment outcomes in clinical practice: The SOURCE Trial
2026 Annals of Oncology article Health Professions Patient-Provider Communication in Healthcare Open access

Evelien N. van Alphen, L.L. Bastiaans, Loïs F van de Water, Steven C. Kuijper, E.S. Kooij, Inge Henselmans, +14 more

0

citations
162TiP DEL-LIVER: An open-label, randomized phase II study of melphalan/HDS induction followed by standard therapy vs standard therapy alone in patients with liver-dominant refractory metastatic colorectal cancer
2026 Annals of Oncology article Medicine Colorectal Cancer Treatments and Studies Open access

D. Arnold, C. Arslan, T. Wirth, J. Maurel, Michael Moche, K-K. Shiu, +12 more

0

citations
614P TGF-β and PD-L1 inhibition with bintrafusp alfa combined with definitive chemoradiation therapy for esophageal squamous cell carcinoma (Tapestry): A single-arm, phase II, investigator-initiated, multicenter, feasibility study
2026 Annals of Oncology article Medicine Esophageal Cancer Research and Treatment Open access

Demi Wekking, Linde M. Veen, Peter S.N. van Rossum, Debby E. Geijsen, Laurens Victor Beerepoot, Irene E.G. van Hellemond, +14 more

0

citations
503P Timing of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation
2026 Annals of Oncology article Medicine Gastric Cancer Management and Outcomes Open access

Denice Kamp, Anne Maria May, R. Kessels, Marije Slingerland, Harm Westdorp, Stella Mook, +3 more

0

citations
Reply to “Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward”
2026 Annals of Oncology letter Medicine Sarcoma Diagnosis and Treatment

César Serrano, Jean‐Yves Blay, Judith V.M.G. Bovée

0

citations
665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC)
2020 Annals of Oncology article Medicine Prostate Cancer Treatment and Research Open access

Bertrand F. TOMBAL, Stephen J. Freedland, Andrew J. Armstrong, Tomasz M. Beer, Arnulf Stenzl, Cora Nanette Sternberg, +8 more

0

citations
P-104 Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy
2021 Annals of Oncology conference-abstract Medicine Gastric Cancer Management and Outcomes Open access

Stefan de Vogel, James Van Schyndle, David Nimke, Ahsan M. Arozullah, Noah Jamie Robinson

0

citations
294P Prevalence and prognostic value of claudin 18.2 expression in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma in Germany
2025 Annals of Oncology article Medicine Pancreatic and Hepatic Oncology Research Open access

Peter Johannes Wild, Marco Groß-Langenhoff, Julia Bein, Martin Glasstetter, Georgia Gourgioti, A. Van Oosten, +3 more

0

citations
2443P Phase I trial of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients (Pts) with advanced prostate cancer (PC)
2025 Annals of Oncology article Medicine Prostate Cancer Treatment and Research Open access

Juan Avitia, N.D. Shore, D.J. George, Michael R. Harrison, David S. Morris, R. Malone, +9 more

0

citations
Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO)
2026 Annals of Oncology article Medicine Esophageal Cancer Research and Treatment Open access

S.S.G. Gangaram Panday, Berend J. van der Wilk, SM Lagarde, Ben M. Eyck, C. Rosman, B.J. Noordman, +94 more

0

citations
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy
2026 Annals of Oncology article Medicine Renal cell carcinoma treatment Open access

Daniel Y.C. Heng, M. Schmidinger, Ray McDermott, S.H. Park, M. Burotto, C. Ciccarese, +24 more

0

citations